Charles Schwab Investment Management Inc. Grows Stock Holdings in Hims & Hers Health, Inc. (NYSE:HIMS)

Charles Schwab Investment Management Inc. increased its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 7.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,796,838 shares of the company's stock after purchasing an additional 129,416 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.82% of Hims & Hers Health worth $43,448,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Crewe Advisors LLC bought a new position in Hims & Hers Health in the fourth quarter worth approximately $28,000. Raleigh Capital Management Inc. lifted its holdings in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company's stock worth $29,000 after buying an additional 1,100 shares during the period. Smartleaf Asset Management LLC lifted its holdings in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares during the period. US Bancorp DE lifted its holdings in Hims & Hers Health by 346.7% during the fourth quarter. US Bancorp DE now owns 1,943 shares of the company's stock worth $47,000 after buying an additional 1,508 shares during the period. Finally, Venturi Wealth Management LLC purchased a new stake in Hims & Hers Health during the fourth quarter worth $48,000. Institutional investors own 63.52% of the company's stock.

Analysts Set New Price Targets

HIMS has been the subject of a number of analyst reports. TD Cowen restated a "buy" rating and set a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Leerink Partners upped their target price on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Truist Financial upped their target price on Hims & Hers Health from $24.00 to $39.00 and gave the stock a "hold" rating in a report on Wednesday, February 26th. Canaccord Genuity Group increased their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Finally, Citigroup reiterated a "sell" rating and set a $27.00 price objective on shares of Hims & Hers Health in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $37.31.

Remove Ads

Insiders Place Their Bets

In other news, CEO Andrew Dudum sold 36,460 shares of the firm's stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the sale, the chief executive officer now directly owns 27,918 shares in the company, valued at $756,298.62. This trade represents a 56.63 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Oluyemi Okupe sold 18,959 shares of the firm's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $25.77, for a total value of $488,573.43. Following the sale, the chief financial officer now owns 132,578 shares in the company, valued at $3,416,535.06. This trade represents a 12.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 890,592 shares of company stock valued at $31,677,291. Company insiders own 17.71% of the company's stock.

Hims & Hers Health Stock Performance

HIMS stock traded down $3.23 during midday trading on Tuesday, reaching $31.46. The stock had a trading volume of 15,187,015 shares, compared to its average volume of 13,542,383. The stock has a market cap of $6.99 billion, a PE ratio of 71.49 and a beta of 1.37. The firm has a fifty day simple moving average of $38.64 and a two-hundred day simple moving average of $28.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.